Background: An impaired HBsAg-secretion can increase HBV oncogenicproperties. Here, we investigate genetic-determinants in HBsAg correlated with HBVinduced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. Methods: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. Results: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P < 0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P < 0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P < 0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P < 0.001). Conclusions: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro / R. Salpini, M. Surdo, N. Warner, M.F. Cortese, D. Colledge, S. Soppe, M.C. Bellocchi, D. Armenia, L. Carioti, F. Continenza, D. Di Carlo, P. Saccomandi, C. Mirabelli, M. Pollicita, R. Longo, S. Romano, G. Cappiello, A. Spanò, P. Trimoulet, H. Fleury, J. Vecchiet, N. Iapadre, A. Barlattani, A. Bertoli, T. Mari, C. Pasquazzi, G. Missale, C. Sarrecchia, E. Orecchini, A. Michienzi, M. Andreoni, S. Francioso, M. Angelico, J. Verheyen, F. Ceccherini-Silberstein, S. Locarnini, C.F. Perno, V. Svicher. - In: ONCOTARGET. - ISSN 1949-2553. - 8:9(2017 Feb 28), pp. 15704-15715. [10.18632/oncotarget.14944]

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

D. Di Carlo;R. Longo;C.F. Perno
;
2017

Abstract

Background: An impaired HBsAg-secretion can increase HBV oncogenicproperties. Here, we investigate genetic-determinants in HBsAg correlated with HBVinduced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. Methods: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. Results: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P < 0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P < 0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P < 0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P < 0.001). Conclusions: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.
English
Cell proliferation; HBsAg mutations; Hepatitis B; Hepatitis B surface antigen; Hepatocellular carcinoma; Adult; Aged; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Female; Gene Frequency; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Host-Pathogen Interactions; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Risk Factors; Mutation; Oncology
Settore MED/07 - Microbiologia e Microbiologia Clinica
Articolo
Esperti anonimi
Pubblicazione scientifica
28-feb-2017
Impact Journals
8
9
15704
15715
12
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro / R. Salpini, M. Surdo, N. Warner, M.F. Cortese, D. Colledge, S. Soppe, M.C. Bellocchi, D. Armenia, L. Carioti, F. Continenza, D. Di Carlo, P. Saccomandi, C. Mirabelli, M. Pollicita, R. Longo, S. Romano, G. Cappiello, A. Spanò, P. Trimoulet, H. Fleury, J. Vecchiet, N. Iapadre, A. Barlattani, A. Bertoli, T. Mari, C. Pasquazzi, G. Missale, C. Sarrecchia, E. Orecchini, A. Michienzi, M. Andreoni, S. Francioso, M. Angelico, J. Verheyen, F. Ceccherini-Silberstein, S. Locarnini, C.F. Perno, V. Svicher. - In: ONCOTARGET. - ISSN 1949-2553. - 8:9(2017 Feb 28), pp. 15704-15715. [10.18632/oncotarget.14944]
open
Prodotti della ricerca::01 - Articolo su periodico
38
262
Article (author)
no
R. Salpini, M. Surdo, N. Warner, M.F. Cortese, D. Colledge, S. Soppe, M.C. Bellocchi, D. Armenia, L. Carioti, F. Continenza, D. Di Carlo, P. Saccomand...espandi
File in questo prodotto:
File Dimensione Formato  
14944-221703-3-PB.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/623191
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact